Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 5/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | KMO | O15229 | 1/20 | 0.57 |
| ▸ | EGFR | P00533 | 1/20 | 0.52 |
| ▸ | FABP1 | P07148 | 1/20 | 0.50 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | RXRA | P19793 | 3/20 | 0.46 |
| ▸ | RXRB | P28702 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15835584 | 0.92 | DHODH (0.58) | DHODHMAPTSMN1; SMN2EGFRLMNA | |
| SCHEMBL10046636 | 0.90 | MAPT (0.68) | DHODHMAPTSMN1; SMN2KMOEGFR | |
| SCHEMBL15835579 | 0.89 | DHODH (0.48) | DHODHMAPTSMN1; SMN2LMNARXRA | |
| SCHEMBL27736451 | 0.89 | DHODH (0.77) | DHODHKMOEGFRFABP1P2RY14 | |
| SCHEMBL1768904 | 0.89 | DHODH (0.77) | DHODHKMOEGFRFABP1P2RY14 | |
| SCHEMBL15835580 | 0.88 | RXRA (0.60) | DHODHMAPTSMN1; SMN2EGFRRXRA | |
| SCHEMBL23671728 | 0.87 | DHODH (0.81) | DHODHMAPTSMN1; SMN2KMOEGFR | |
| Hydrochloric Acid SCHEMBL9622264 | 0.87 | DHODH (0.74) | DHODHKMOEGFRFABP1P2RY14 | |
| SCHEMBL28462472 | 0.87 | DHODH (0.75) | DHODHKMOEGFRFABP1P2RY14 | |
| Hydrochloric Acid SCHEMBL29446586 | 0.87 | DHODH (0.74) | DHODHKMOEGFRFABP1P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008054454-A2 | NITROGEN-CONTAINING HETEROCYCLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF AS ANTIVIRAL AGENTS | TRANSTECH PHARMA, INC. (US) | 2008-05-08 | — | — | WO | disclosed |
| US-20070219239-A1 | Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219239-A1 | Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents | NUDT1, PNP, NME2 | DHODH 376/4885MAPT 4509/4885SMN1; SMN2 2041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.